抗脓肿分枝杆菌感染的替代疗法
本叙述性综述通过检索PubMed和MEDLINE至2023年6月,总结了抗脓肿分枝杆菌(Mab)感染的替代策略,包括宿主导向疗法、老药新用、噬菌体疗法、抗毒力策略、精油和吸入疗法,并讨论了使用合适实验方法评估其活性的重要性。作者认为替代治疗可能是应对Mab所致疾病抗菌药物耐药负担的有效工具。
要点
- 脓肿分枝杆菌对多种药物固有和获得性耐药,标准方案疗程超过6个月且毒性大、疗效欠佳。
- 替代策略包括宿主导向疗法、老药新用、噬菌体疗法、抗毒力策略、精油和吸入疗法。
- 作者认为替代治疗可能是应对Mab耐药负担的有效工具,并强调需用合适实验方法评估活性。
核心结论
- 作者认为替代治疗可能是应对脓肿分枝杆菌所致疾病抗菌药物耐药负担的有效工具。
研究设计与样本
- 叙述性综述,检索PubMed和MEDLINE至2023年6月,检索词为「Mycobacterium abscessus」「antimicrobial」和「alternative therapies」,并从主要检索所得文章获取额外相关参考文献。
主要发现
- 脓肿分枝杆菌被认为是人类最具致病性的快速生长分枝杆菌,引起肺部和肺外疾病,尤其在囊性纤维化患者中。
- 脓肿分枝杆菌对许多药物显示固有和获得性耐药,导致治疗选择有限且总体预后差。
- 标准治疗方案持续超过6个月,由药物组合构成,理想情况下包括大环内酯类和阿米卡星,但毒性和疗效欠佳。
关键数值与推荐
- 标准治疗方案持续超过6个月,由药物组合构成,理想情况下包括大环内酯类和阿米卡星。
- 替代疗法涵盖宿主导向疗法、老药新用、噬菌体疗法、抗毒力策略、精油和吸入疗法。
临床怎么用
- 作者认为替代治疗可能是应对脓肿分枝杆菌所致疾病抗菌药物耐药负担的有效工具。
- 作者强调使用合适的实验测定方法来评估替代策略的活性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mycobacterium abscessus (Mab) is considered as the most pathogenic rapid-growing mycobacteria in humans, causing pulmonary and extra-pulmonary diseases, especially in patients with cystic fibrosis. Mab shows intrinsic and acquired resistance to many drugs, leaving limited treatment options that lead to a generally poor prognosis. The standard therapeutic regimen last for more than 6 months and consists of a drug cocktail that ideally includes a macrolide and amikacin. Yet, toxicity and efficacy are suboptimal due also to the high toxicity. There is a need to introduce innovative and out-of-the-box approaches to improve treatments. OBJECTIVES: In this narrative review, we summarize the recent research on the alternative strategies proposed and discuss the importance of using appropriate experimental assays to assess their activity. SOURCES: Included articles were identified by searching PubMed and MEDLINE until June 2023. The search terms were 'Mycobacterium abscessus', 'antimicrobial', and 'alternative therapies'. Additional relevant references were obtained from articles retrieved from the primary search. CONTENT: Therapies against Mab including host directed therapies, repurposed drugs, phage therapy, anti-virulence strategies, essential oils, and inhalation therapies. IMPLICATIONS: Alternative treatments may represent a valid tool to cope the burden of antimicrobial resistance in Mab-caused diseases.
引用
- Palucci I, Delogu G. Alternative therapies against Mycobacterium abscessus infections. Clin Microbiol Infect. 2023. PMID: 37820951. doi:10.1016/j.cmi.2023.10.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。